Descripción del proyecto
Un material innovador para acelerar el desarrollo de fármacos
La purificación es fundamental en todas las industrias químicas. Con todo, las técnicas actuales para llevarla a cabo son caras, lentas y consumen mucha energía, lo que plantea problemas para la salud, la seguridad y el medio ambiente. También son la razón por la que la purificación constituye un obstáculo para el descubrimiento de fármacos. El proyecto SEP43, financiado con fondos europeos, accederá al mercado del descubrimiento de fármacos gracias a un material multicapilar rupturista que resuelve problemas relacionados con la purificación en las industrias farmacéutica y química. Esta tecnología revolucionaria reduce en un orden de magnitud la presión funcional necesaria para separar moléculas. Este material, protegido por seis patentes internacionales, es el primero que permite un desarrollo más rápido de fármacos y productos químicos a un coste menor a través de un proceso industrial más seguro y ecológico.
Objetivo
SEPARATIVE SAS is an industrial startup located in the heart of the “Chemical Valley” in France, surrounded by major pharmaceutical and chemical companies. We have designed, developed, manufactured a small series, and achieved a breakthrough multicapillary material that solves problems related to purification in the pharmaceutical and chemical industries. From this innovation, we have obtained 5 patents for the material and its manufacturing process. Our chromatography column, SEP43, is the first to meet the industry need to purify molecules to high purity quickly and at low pressure.
Purification is key for all chemical industries. Yet, current techniques are expensive, slow, energy intensive, and create issues for health, safety and the environment. Hence, purification has become a lock in drug discovery. SEP43 would enable faster drug and chemical development, at lower cost, with a safer and more eco-friendly manufacturing process. This is in line with the European Green Deal as the use of our product would save up to 20,000 mt of CO2E from solvent incineration, 8000kw/h electricity consumption and solvent cost of €9.6M/year.
The current pharmaceutical chromatography market is worth over 3B€. Our technology is well-positioned to rapidly become the preferred solution for both R&D and process-scale purification. Our strategy is to enter the market in drug discovery and to follow the molecule life cycle toward the process-scale before branching out to other chemical sectors. This first business case will generate the needed cash flow to invest in further product development and promotion.
Our prototypes have been successfully tested at TRL6 by independent laboratories. But as an equity-intensive and deep-tech project, we have been unable to attract sufficient funding to scale-up and automate our production line. The current project would enable us to deploy this strategy and provide a much-needed breakthrough that can be rapidly adopted by a very large market.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
69190 Saint Fons
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.